Daye Peak Held Seminar on Low-Alkali Cement Production
Release time:
2020-07-22
Daye Peak Held Low-alkali Cement Production Seminar
News In order to ensure the quality of low-alkali cement to meet the requirements of key project contract indicators, to increase the market share of "Peak " brand cement high-end products, 5# December, Daye Peak Cement Company organized a special seminar, special discussions on low-alkali cement ingredients, production, quality management and other matters.
low-alkali cement refers to cement with low content of alkali metal oxides (potassium oxide and sodium oxide) (total alkali content is calculated as equivalent sodium oxide (Na2O + 0.658K2O ), and low-alkali cement requires total alkali content lower than 0.6% ). In engineering construction, the alkaline substance in the concrete raw materials chemically reacts with the active ingredients to generate swelling substances or water-absorbing swelling substances, which in turn causes the concrete to produce internal self-expansion stress and crack, which is called "alkali aggregate reaction " (abbreviated as AAR) . Because the alkali aggregate reaction generally occurs gradually after several years after the concrete is formed, the durability of the concrete is reduced as a result, and in severe cases, the concrete will lose its use value. Moreover, because the reaction occurs in the whole concrete, the damage caused is difficult to prevent, prevent, repair and rescue, and is called "concrete cancer " . Therefore, many projects, especially railways, bridges and other large-scale projects require the use of low-alkali cement. Since its production, Daye Peak has participated in the construction of key projects in many countries, provinces and cities, and has accumulated a lot of experience in the production of low-alkali cement.
The production of low-alkali cement requires the use of low-alkali clinker, low-alkali gypsum and low-alkali mineral admixtures. Low alkali clinker must be produced with low alkali limestone and other low alkali raw materials. At the seminar, Daye peak management team and quality control department, manufacturing department, mining and other relevant personnel attended. Combined with the limestone resources and early production experience of Daye Peak Mine, a detailed and comprehensive discussion was carried out. The Quality Control Department puts forward a plan for the batching scheme and process control of low-alkali cement, and formulates detailed alkali control measures from the work links such as the quality control of mine limestone, the substitution of low-grade sandstone for clay batching, and the adjustment of mixed material varieties. The mining department, manufacturing department and other relevant departments put forward their views and suggestions on the problems that may be faced in the actual production process.
Daye Peak requires all relevant departments to attach great importance to and cooperate closely, optimize the production organization in strict accordance with the predetermined quality control index requirements, and minimize the adverse factors affecting the operation quality of the kiln, so as to ensure the high quality and high yield of the kiln, ensure the stable production of low alkali cement, and provide customers with high-quality products. (Wang Yuhua Fan Liangwu)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page